These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18586297)

  • 21. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
    Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
    J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine.
    Nixon DF; Donahoe SM; Kakimoto WM; Samuel RV; Metzner KJ; Gettie A; Hanke T; Marx PA; Connor RI
    Virology; 2000 Jan; 266(1):203-10. PubMed ID: 10612675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus.
    Stahl-Hennig C; Dittmer U; Nisslein T; Petry H; Jurkiewicz E; Fuchs D; Wachter H; Mätz-Rensing K; Kuhn EM; Kaup FJ; Rud EW; Hunsmann G
    J Gen Virol; 1996 Dec; 77 ( Pt 12)():2969-81. PubMed ID: 9000087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys.
    Walther-Jallow L; Nilsson C; Söderlund J; Ten Haaft P; Mäkitalo B; Biberfeld P; Böttiger P; Heeney J; Biberfeld G; Thorstensson R
    J Gen Virol; 2001 Jul; 82(Pt 7):1601-1612. PubMed ID: 11413371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.
    Lifson JD; Haigwood NL
    Cold Spring Harb Perspect Med; 2012 Jun; 2(6):a007310. PubMed ID: 22675663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Live attenuated AIDS viruses as vaccines: promise or peril?
    Ruprecht RM
    Immunol Rev; 1999 Aug; 170():135-49. PubMed ID: 10566148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.
    Mossman SP; Bex F; Berglund P; Arthos J; O'Neil SP; Riley D; Maul DH; Bruck C; Momin P; Burny A; Fultz PN; Mullins JI; Liljeström P; Hoover EA
    J Virol; 1996 Mar; 70(3):1953-60. PubMed ID: 8627721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
    Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
    J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is an HIV vaccine possible?
    Wilson NA; Watkins DI
    Braz J Infect Dis; 2009 Aug; 13(4):304-10. PubMed ID: 20231996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection.
    Kwofie TB; Miura T; Ibuki K; Enose Y; Suzuki H; Ui M; Kuwata T; Hayami M
    Arch Virol; 2002 Jun; 147(6):1091-104. PubMed ID: 12111421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates.
    Warren J
    J Med Primatol; 2002 Aug; 31(4-5):237-56. PubMed ID: 12390546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.
    Izumi Y; Ami Y; Matsuo K; Someya K; Sata T; Yamamoto N; Honda M
    J Virol; 2003 Dec; 77(24):13248-56. PubMed ID: 14645581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection of macaques against simian immunodeficiency virus infection with inactivated vaccines: comparison of adjuvants, doses and challenge viruses. The European Concerted Action on 'Macaque Models for AIDS Research'.
    Vaccine; 1995 Feb; 13(3):295-300. PubMed ID: 7631516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus.
    Lewis MG; Yalley-Ogunro J; Greenhouse JJ; Brennan TP; Jiang JB; VanCott TC; Lu Y; Eddy GA; Birx DL
    J Virol; 1999 Feb; 73(2):1262-70. PubMed ID: 9882330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus.
    Genescà M; Skinner PJ; Hong JJ; Li J; Lu D; McChesney MB; Miller CJ
    J Virol; 2008 Nov; 82(22):11181-96. PubMed ID: 18787003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses.
    Abel K; Compton L; Rourke T; Montefiori D; Lu D; Rothaeusler K; Fritts L; Bost K; Miller CJ
    J Virol; 2003 Mar; 77(5):3099-118. PubMed ID: 12584336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Live attenuated SIV vaccines are not effective in a postexposure vaccination model.
    Linhart H; Gundlach BR; Sopper S; Dittmer U; Mätz-Rensing K; Kuhn EM; Müller J; Hunsmann G; Stahl-Hennig C; Uberla K
    AIDS Res Hum Retroviruses; 1997 May; 13(7):593-9. PubMed ID: 9135877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using SHIVs to develop an anti-HIV-1 live-attenuated vaccine.
    Kuwata T; Miura T; Hayami M
    Trends Microbiol; 2001 Oct; 9(10):475-80. PubMed ID: 11597447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.